Evgen Pharma Share Discussion Threads

[moneymunch] 15/9/2020 07:02

RNS Number : 9626Y
Evgen Pharma PLC
15 September 2020


Evgen Pharma plc

("Evgen" or the "Company")



Licence agreement with Juvenescence for non-pharmaceutical applications

$10.5m milestones plus royalties on sales



Evgen Pharma plc (AIM: EVG), the clinical-stage drug development company, is pleased to announce the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence Ltd ("Juvenescence"). In particular, Juvenescence intends to market and sell a high-end nutritional health product containing a defined dose of sulforaphane extracted from natural sources. Under the terms of the license agreement ("the Agreement"), Evgen will receive milestone and option payments of up to $10.5m as detailed below. Evgen will also receive royalties on future product sales.



This agreement monetises one element of Evgen's sulforaphane technology platform within a timescale considerably shorter than that typical of pharmaceutical development. Evgen's focus will remain on progressing its therapeutic programmes, and the Agreement contains provisions which ensure a clear differentiation between potential nutritional health products and pharmaceutical products, including limitations on daily dose.



Juvenescence will deploy the Sulforadex® stabilisation technology to manufacture and market a nutritional health product containing a defined and stable dose of sulforaphane, derived from natural sources. This contrasts with the synthetic sulforaphane which is used in SFX-01, the Company's lead therapeutic product. It is envisaged that product launch by Juvenescence will occur within the next two years.



About Juvenescence (www.juvenescence.ltd)

Juvenescence is a life sciences company based on a completely new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies, focused on increasing how long people live in health by preventing the diseases of aging in the first place. JuvLife, a division of Juvenescence, is focused on the development and commercialisation of scientifically proven and branded nutritional health products and medical foods that can improve human longevity and quality of life.



Details of the Agreement

The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement.



Barry Clare, Executive Chairman of Evgen, said: ''This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. ''



Colin Watts, Chief Executive Officer of JuvLife Division, said: "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen.''

[moneymunch] 14/9/2020 16:31

Lol...Teeoffman....you certainly are....;-)

ps EVG......" A safe haven for all reasonable SNG shareholders "....ha ha ha ha ;-)

[toffeeman] 14/9/2020 16:28

>> MM: YAWN!!

[jusjusjus] 14/9/2020 15:51

keeping a tight spread now

[moneymunch] 14/9/2020 15:33

Wouldn't be surprised to see a significant surge into close in anticipation of imminent news...Gla ;-)

[moneymunch] 14/9/2020 13:51

and looking better by the minute...potential Transformational news at anytime, now!!! :-)

[bumpa33] 14/9/2020 13:14

nice (intra day) reversal so far.

[moneymunch] 14/9/2020 13:07

Champagne's on ice...Tick Tock :-)

[moneymunch] 14/9/2020 08:27

Ps 30 degrees forecast in my neck of the woods...Scorchio!!!😎😎
28526;

[moneymunch] 14/9/2020 08:25

Good Morning Bumpa, excitement building in anticipation of a stellar Rns or two...Cheers :-)

[bumpa33] 14/9/2020 07:54

Morning mm - let’s see what the week brings. Hopefully some update(s) or someone’s gonna get crossed off my Xmas card list!

[moneymunch] 12/9/2020 23:59

The SNG guild model village....????....;-))))

[moneymunch] 12/9/2020 14:23

Evgen and SFX-01....a prime target for BIG Pharma imho.....Gla ;-)

[moneymunch] 12/9/2020 14:20

15/6/20

Barry Clare, Executive Chairman of Evgen Pharma, said: "We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear. These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor. We therefore believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01. On behalf of myself and the Board, I would like to thank our shareholders for their continued support and we look forward to updating the market with positive news in the coming year."

[moneymunch] 12/9/2020 14:20

Review

Nrf2: Redox and Metabolic Regulator of Stem Cell State and Function

Nuclear factor erythroid 2-related factor 2 (Nrf2) is ubiquitously expressed in most eukaryotic cells and functions to induce a broad range of cellular defenses against exogenous and endogenous stresses, including oxidants, xenobiotics, and excessive nutrient/metabolite supply.

Because the production and fate of stem cells are often modulated by cellular redox and metabolic homeostasis,important roles of Nrf2 have emerged in the regulation of stem cell quiescence, survival, self-renewal, proliferation, senescence, and differentiation. In a rapidly advancing field, this review summarizes Nrf2 signaling in the context of stem cell state and function and provides a rationale for Nrf2 as a therapeutic target in stem cell-based regenerative medicine.



..........................

Highlighted STAT3 as a potential drug target for cancer therapy

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor micro environment, and present inhibitors of STAT3 signaling cascades.

Keywords: Cancer stem cells, Cancer therapy, Immune suppression, STAT3, Tumor micro environment

[brasso3] 11/9/2020 12:05

I am still here watching from behind a curtain of worry (on all stocks).

[moneymunch] 11/9/2020 09:24

Yep, it certainly would Bumpa....but keep it quiet...;-))))

[bumpa33] 11/9/2020 09:21

Next week would be a really “great” time for an update, wouldn’t it? :)

[moneymunch] 10/9/2020 16:12

Looks like they want to hoover UP every single share on the cheap before they make the Major announcement imho.....we had the massive share transfers and we've had the constant share accumulation of every single share sold on a daily basis for weeks and months....mine are held very tightly indeed.....Gla ;-))))